[go: up one dir, main page]

WO2000051684A2 - Regulateurs de transacylase independante de la coenzyme a comme medicaments psychotropes - Google Patents

Regulateurs de transacylase independante de la coenzyme a comme medicaments psychotropes Download PDF

Info

Publication number
WO2000051684A2
WO2000051684A2 PCT/GB2000/000779 GB0000779W WO0051684A2 WO 2000051684 A2 WO2000051684 A2 WO 2000051684A2 GB 0000779 W GB0000779 W GB 0000779W WO 0051684 A2 WO0051684 A2 WO 0051684A2
Authority
WO
WIPO (PCT)
Prior art keywords
depression
coait
drugs
disease
inhibit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2000/000779
Other languages
English (en)
Other versions
WO2000051684A3 (fr
Inventor
David Frederick Horrobin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scarista Ltd
Original Assignee
Scarista Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scarista Ltd filed Critical Scarista Ltd
Publication of WO2000051684A2 publication Critical patent/WO2000051684A2/fr
Publication of WO2000051684A3 publication Critical patent/WO2000051684A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Definitions

  • Schizophrenia depression and bipolar disorder (manic-depression) are the major common psychiatric disorders. Schizophrenia is usually treated by drugs which block dopamine and serotonin receptors. Bipolar disorder is usually treated by lithium or by one of a range of drugs which also have anti-epileptic actions. Depression is usually treated by drugs which in some way modify catecholamine or serotonin function or metabolism.
  • Arachidonic acid is generally recognised as playing a major role in immune and inflammatory reactions. In the process of many such reactions AA is released from a phospholipid compartment. The released AA may act by itself or may be converted to a range of prostaglandin, leukotriene, or other oxygenated metabolites. This range of substances is fundamental to a normal immune response and to the stimulation of secretion of interleukins, interferons and other cytokines.
  • CoAIT transfers AA from other phospholipids to particular phospholipids, usually ones with an ether linkage at the Snl position, which are the sources of the AA released during activation of macrophages, lymphocytes, polymorphonuclear leucocytes and other cells of the inflammation and immune systems.
  • the donor phospholipids are often but not always phosphatidylcholines with an AA group at the Sn2 position and an acyl-link to another fatty acid at the Snl position.
  • the recipient phospholipids are usually lysophospholipids from which the fatty acid at the Sn2 position has been removed.
  • lysphospholipids often have an alkyl or an alkenyl group at the Snl position, and are also often of the phosphatidyl ethanolamine class.
  • the recipient phospholipids become enriched in AA which is then released during immune and inflammatory reactions.
  • CoAIT inhibitors have recently been developed as anti-inflammatory agents but have not been proposed to have anti-depressant actions.
  • Several different classes of compound have been reported to inhibit CoAIT. They include agents which interact with cysteine, serine esterase inhibitors such as phenyl-methyl- sulfonyl fluoride and N-tosyl-L-phenylalanine chloromethyl ketone, p- nitrophenyl phosphate and M-aminophenyl boronic acid, and agents which can inhibit the enzyme lecithin choline acyltransferase which has a similar mode of action to CoAIT (Winkler & Chilton, 1995).
  • SK ⁇ F98625 diethyl 7-(3,4,5-triphenyl- 2-oxo-2,3-dihydro-imidazol-l-yl)heptane-phosphate
  • SK ⁇ F 45905 2-[2-[3- (4-c--doro-3-trifluoro-methylphenyl)ureido]-4,5-dichlorobenzenesulfonic acid inhibitors
  • inhibitors which have been described include SK ⁇ F 105809 (2-(4-methylsulf ⁇ nylphenyl)-3-(4-pyridyl)-6,7- dihydro-[5H]-pyrrolol[l,2-a]imidazole), SK ⁇ F 105561 (2-(4-methylthiophenyl)- 3-(4-pyridyl)-6,7-dihydro-[5H]-pyrrolol[l,2-a]imidazole and other pyrroloimidazoles (PJ Marshall et al, Biochemical Pharmacology 1991 ; 42: 813-824) and a range of beta-lactam derivatives, including SB 212047 (4- methoxbenzyl(3S,4R)-6-bromo-6-[(l-methyl-l,2,3-triazol-4-yl)- hydroxymethyljpenicillanate) and SB216754 ((3S, 4R)-4-[(isobuteny
  • CoAIT is overactive, in schizophrenia it is underactive.
  • immune and inflammatory reactions are impaired (DF Horrobin et al, Schizophrenia Research 1994; 13:195-207), and the response to niacin, which activates arachidonic acid release, is seriously defective (P Ward et al, Schizophrenia Research 1998; 29:269-274).
  • Drugs which activate CoAIT will therefore be important and effective in schizophrenia.
  • CoAIT inhibitors or activators which can penetrate the brain.
  • One way of dong this is to make them more lipophilic. This can be done by attaching to them fatty acids with 12-30 carbon atoms and 0-6 double bonds. It can also be done by incorporating them into compounds such as these described in international patent applications WO 96/34846 and WO 96/34855.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne l'utilisation de médicaments capables d'inhiber une transacylase indépendante de la coenzyme A dans le traitement ou la production d'un médicament destiné au traitement de troubles psychiatriques.
PCT/GB2000/000779 1999-03-03 2000-03-03 Regulateurs de transacylase independante de la coenzyme a comme medicaments psychotropes Ceased WO2000051684A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9904895.1A GB9904895D0 (en) 1999-03-03 1999-03-03 Regulators of coenzyme-A-independent transacylase as psychotropic drugs
GB9904895.1 1999-03-03

Publications (2)

Publication Number Publication Date
WO2000051684A2 true WO2000051684A2 (fr) 2000-09-08
WO2000051684A3 WO2000051684A3 (fr) 2001-01-04

Family

ID=10848886

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/000779 Ceased WO2000051684A2 (fr) 1999-03-03 2000-03-03 Regulateurs de transacylase independante de la coenzyme a comme medicaments psychotropes

Country Status (2)

Country Link
GB (1) GB9904895D0 (fr)
WO (1) WO2000051684A2 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0289204B1 (fr) * 1987-04-27 1991-07-17 Efamol Holdings Plc Compositions pharmaceutiques contenant des sels de lithium
DK0626969T3 (da) * 1992-02-11 2000-10-30 Smithkline Beecham Corp CoA-IT- og PAF-inhibitorer
JPH11511130A (ja) * 1995-07-25 1999-09-28 スミスクライン・ビーチャム・コーポレイション ＣｏＡ−非依存性トランスアシラーゼの阻害およびアポトーシス
DK0956013T3 (da) * 1996-10-11 2003-08-04 Scarista Ltd Farmaceutisk præparat indeholdende eicosapentaensyre og/eller stearidonsyre
AU7222598A (en) * 1997-04-29 1998-11-24 Scotia Holdings Plc Treatment of depression and anxiety using docosahexaenoic acid or natural antioxidants

Also Published As

Publication number Publication date
GB9904895D0 (en) 1999-04-28
WO2000051684A3 (fr) 2001-01-04

Similar Documents

Publication Publication Date Title
EP2457567B1 (fr) Agent doté d'une activité de type facteur neurotrophe
JP3940810B2 (ja) アデノシンモノホスフェートデアミナーゼの新規阻害剤
EP0132089B1 (fr) Compositions d'acide gras
JPH06197735A (ja) 食品組成物
Peruzzotti-Jametti et al. Metabolic control of smoldering neuroinflammation
US5753702A (en) Arachidonic acid metabolite, 16-hete
Smith Modulation of phagocytosis by and lysosomal enzyme secretion from guinea-pig neutrophils: effect of nonsteroid anti-inflammatory agents and prostaglindins.
AU5141293A (en) Substituted quinuclidines as substance p antagonists
HK1039564A1 (en) Highly purified ethyl epa and other epa derivatives for neurological disorders
EP0071357B1 (fr) Composition pharmaceutique et diététique pour augmenter la production de la pg de la série l
Lewis et al. Arachidonic acid derivatives as mediators of asthma
US6562988B2 (en) Methods and products relating to 16-HETE analogs
Longoni et al. Inhibition of lipid peroxidation by N-acetylserotonin and its role in retinal physiology
US5852052A (en) Treatment of lyso paf-mediated mental or neuronal disorders with lyso paf or paf antagonists and procedure for determining their efficacy
CA2131992A1 (fr) Methodes et compositions a base d'antipyretique et d'analgesique, renfermant du r-etodolac optiquement pur
EP0028257B1 (fr) L-threonine pour la regulation des niveaux de glycine dans le cerveau et la moelle epiniere
Leung et al. Modulation of the development of cell-mediated immunity: possible role of the products of the cyclo-oxygenase and the lipoxygenase pathways of arachidonic acid metabolism
WO2000051684A2 (fr) Regulateurs de transacylase independante de la coenzyme a comme medicaments psychotropes
Visioli et al. Membrane lipid degradation is related to interictal cortical activity in a series of seizures
US5731354A (en) Treatment for the inhibition of neuro-degenerative disease states
US6177476B1 (en) Nutritional supplements for replenishing plasmalogens
WO2018187647A1 (fr) Procédés et compositions destinés au traitement de maladies, troubles ou états neurologiques
Mulqueen et al. Oral, anti-inflammatory activity of a potent, selective, protein kinase C inhibitor
US4405629A (en) Process for increasing glycine levels in the brain and spinal cord
Csato et al. Effect of BN 52021, a platelet activating factor antagonist, on experimental murine contact dermatitis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

122 Ep: pct application non-entry in european phase